The Leukemia & Lymphoma Society launches Impact Research grants to help underserved patients access to clinical trialsPosted On: May 6, 2021
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical TrialsRead More
Background and Purpose
Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown.Read More
RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.Read More
Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.